Mood Disorders: Premenstrual Dysphoric Disorder

2006 ◽  
pp. 274-277
Keyword(s):  
Mood Disorders ◽  
Premenstrual Dysphoric Disorder

scholarly journals Effect of physical and sexual violence during childhood and/or adolescence on the development of menstrual related mood disorders: A systematic review and meta-analysis

Salud Mental ◽  
2021 ◽  
Vol 44 (3) ◽  
pp. 145-153
Author(s):  
Dannia Islas-Preciado ◽  
Karla Flores-Celis ◽  
Jorge González-Olvera ◽  
Erika Estrada-Camarena
Keyword(s):  
Systematic Review ◽  
Sexual Violence ◽  
Mood Disorders ◽  
Premenstrual Syndrome ◽  
Early Life ◽  
Web Of Science ◽  
Meta Analysis ◽  
Premenstrual Dysphoric Disorder ◽  
Life Stages ◽  
Early Life Stages

Background. Abuse in early life stages has been proposed as an etiological risk factor for developing menstrually-related mood disorders (MRMDs). Objetive. To evaluate whether there is a relation between the occurrence of physical and/or sexual violence in childhood and/or adolescence and the development of MRMDs in adulthood. Method. A systematic search was conducted in PubMed, Web of Science, and ScienceDirect, with the route (“Premenstrual Syndrome”[Mesh]) OR (“Premenstrual Dysphoric Disorder”[MeSH]) AND (“Violence”[Mesh]) / (“menstrually-related mood disorders” AND “abuse”). Fifty-four articles were initially reviewed and 32 were excluded based on the criteria. Twenty-two articles were thoroughly reviewed. Finally, five articles (publication years 2014, 2013, 2012, 2007, and 2003) were included in the systematic review and submitted to a meta-analysis. Results. Results indicate that having been exposed to physical and/or sexual violence in childhood and/or adolescence increases 1.99 times the risk of experiencing MRMDs in adulthood in comparison with women who did not experience that type of violence (odds ratio [OR] = 1.99; 95% confidence interval [1.58, 2.51]). Discussion and conclusion. The present work provides evidence that a woman who experienced violence through physical and/or sexual abuse during childhood and/or adolescence has a greater risk of developing MRMDs in adulthood.

scholarly journals Premenstrual Exacerbations of Mood Disorders: Findings and Knowledge Gaps

2021 ◽  
Vol 23 (11) ◽  
Author(s):  
Christine Kuehner ◽  
Sibel Nayman
Keyword(s):  
Bipolar Disorder ◽  
Mood Disorders ◽  
Case Reports ◽  
Unipolar Depression ◽  
Premenstrual Dysphoric Disorder ◽  
Clinical Samples ◽  
Severe Illness ◽  
Systematic Research ◽  
Clear Differentiation ◽  
Underlying Mechanisms

Abstract Purpose of Review In contrast to premenstrual dysphoric disorder (PMDD), premenstrual exacerbations (PMEs) of ongoing mood disorders are understudied. The aim of this review is to describe diagnostic issues, epidemiology, underlying mechanisms, and treatment for PME in unipolar depression and bipolar disorder, and to discuss clinical and research implications. Recent Findings Community-based and clinical studies estimate that in women with mood disorders around 60% report PME, while some women with bipolar disorder also show symptom exacerbations around ovulation. In general, PME predicts a more severe illness course and an increased burden. While heightened sensitivity to fluctuations of sex hormone levels across the menstrual cycle appears to contribute to PME and PMDD, the overlap of their underlying biological mechanisms remains unclear. Beneficial treatments for PMDD show less or no efficacy in PME. Pharmacological treatments for PME in mood disorders predominantly seem to profit from adjustable augmentation of treatment dosages during the luteal phase for the underlying disorder. However, the evidence is sparse and mainly based on earlier small studies and case reports. Summary Previous research is mainly limited by the lack of a clear differentiation between PME and PMDD comorbidity with mood disorders. More systematic research with uniformly defined and prospectively assessed subgroups of PME in larger epidemiological and clinical samples is needed to receive reliable prevalence estimates and information on the clinical impact of PME of mood disorders, and to uncover underlying mechanisms. In addition, larger randomized controlled trials are warranted to identify efficacious pharmacological and psychotherapeutic treatments for affected women.

scholarly journals Is there a role for reproductive steroids in the etiology and treatment of affective disorders?

2018 ◽  
Vol 20 (3) ◽  
pp. 187-196 ◽  
Keyword(s):  
Mood Disorders ◽  
Affective Disorders ◽  
Affective State ◽  
Premenstrual Dysphoric Disorder ◽  
Differential Sensitivity ◽  
Therapeutic Implications ◽  
Affective Dysregulation ◽  
Reproductive Endocrine ◽  
Clinical Models ◽  
Reproductive Steroids

A variety of hormones have been shown to play a role in affective disorders. Reproductive steroids are particularly informative in our efforts to understand the pathophysiology of affective dysregulation for several reasons: i) Reproductive endocrine-related mood disorders (premenstrual dysphoric disorder, perinatal depression, perimenopausal depression) are wonderful clinical models for investigating the mechanisms by which affective state changes occur; ii) Reproductive steroids regulate virtually every system that has been implicated as disturbed in the ontogeny of affective disorders; iii) Despite the absence of a reproductive endocrinopathy a triggering role in the affective disturbance of reproductive mood disorders has been shown clearly for changes in reproductive steroids. The existing data, therefore, support a differential sensitivity to reproductive steroids in reproductive mood disorders such that an abnormal affective state is precipitated by normal changes in reproductive steroids. The therapeutic implications of these findings for affective illness are discussed.

Mood Disorders

2014 ◽  
Author(s):  
Licínia Ganança ◽  
David A. Kahn ◽  
Maria A. Oquendo
Keyword(s):  
Bipolar Disorder ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Mood Disorders ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Premenstrual Dysphoric Disorder ◽  
Major Depressive ◽  
Somatic Therapy ◽  
Mixed Features ◽  
Symptom Ratings

This chapter discusses the mood disorders. Major depressive disorder is characterized by neurovegetative changes, anhedonia, and suicidal ideation. Persistent depressive disorder is a milder form of depression, lasting for at least 2 years, with little or no remission during that time... Psychotic features can occur in both depressive and manic episodes. Premenstrual dysphoric disorder is diagnosed through use of a prospective daily symptom ratings log showing a cyclical pattern over at least 2 consecutive months. Patients with mood episodes with mixed features have a high risk of suicide. Some patients with bipolar disorder and major depressive disorder may develop catatonic features characterized by marked psychomotor disturbance. Selective serotonin reuptake inhibitors (SSRIs) are the usual first-line medication treatment for patients with major depressive disorder. For patients with bipolar disorder the mainstays of somatic therapy are lithium and the anticonvulsants valproate and carbamazepine.

Sign in / Sign up

Export Citation Format

Share Document